Covance Receives Highest Level of Phase I Accreditation

-Leeds clinic receives MHRA accreditation for providing highest level of
clinical trial patient safety-

PRINCETON, N.J., July 30 /PRNewswire/ -- Covance Inc. today announced that it
has received standard and supplementary accreditation for the conduct of
clinical pharmacology in Europe by the Medicines and Healthcare products
Regulatory Agency (MHRA). This voluntary accreditation process provides
clinical trial volunteers and sponsors with confidence that research
facilities and studies meet the industry's highest safety standards.

This accreditation was awarded to Covance's clinical research unit in Leeds,
United Kingdom, where the company conducts first-in-human studies, including
trials requiring a review of risk factors by the Expert Advisory Group.

"Covance delivers the highest level of data quality and patient safety for
first-in-human trials, which is confirmed by the MHRA accreditation," said Rob
Aspbury, M.D., managing director, clinical research services, Covance. "As an
industry leader in clinical pharmacology, Covance provides superior experience
and expertise in study design and conduct to support today's increasingly
complex first-in-human trials."

MHRA accreditation was introduced to ensure the highest level of patient
safety for early clinical development by providing more information about
trial facilities. The process includes formal routine inspections that
provide additional scope and depth to existing procedures for good clinical
practice inspections.

Covance's clinical pharmacology expertise includes full-time physicians,
clinical pharmacologists, registered pharmacists and more than 30 Advanced
Life Support (ALS) trained nurses. The industry leader in the conduct of
clinical pharmacology studies, Covance offers more than 500 beds across nine
Phase I clinics located in the United States, United Kingdom, and Switzerland.

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $1.7 billion, global operations in more than 25
countries, and more than 10,000 employees worldwide. Information on Covance's
products and services, recent press releases, and SEC filings can be obtained
through its website at www.covance.com.

Statements contained in this press release, which are not historical facts,
are forward-looking statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All such forward-looking
statements including the statements contained herein regarding anticipated
trends in the Company's business are based largely on management's
expectations and are subject to an qualified by risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, without
limitation, competitive factors, outsourcing trends in the pharmaceutical
industry, levels of industry research and development spending, the Company's
ability to continue to attract and retain qualified personnel, the fixed price
nature of contracts or the loss of large contracts, and other factors
described in the Company's filings with the Securities and Exchange
Commission. Covance and the Covance are registered service marks of Covance
in the United States and other countries.

SOURCE Covance Inc.

Media Relations for Covance Inc., +1-609-452-4275, or Investor Relations for
Covance Inc. +1-609-452-4807